<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02124421</url>
  </required_header>
  <id_info>
    <org_study_id>MMC-2014-17</org_study_id>
    <nct_id>NCT02124421</nct_id>
  </id_info>
  <brief_title>Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer</brief_title>
  <acronym>CRS/HIPEC</acronym>
  <official_title>Phase II Randomized Study: Cytoreductive Surgery (CRS) With/Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Adjuvant Chemotherapy as Initial Treatment of Ovarian, Fallopian Tube, &amp; Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercy Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercy Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Community hospital based phase II (prospective randomized) study to evaluate the toxicity of
      cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in newly
      diagnosed, otherwise untreated, advanced stage (stage III/IV) epithelial ovarian, fallopian
      tube, and primary peritoneal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoints:

        -  To assess the feasibility of recruitment

        -  Compare complication rates between the two study arms: CRS with HIPEC and CRS alone.

      Secondary endpoints:

        -  To determine risk factors for morbidity and mortality

        -  Assess completion rate of 6 cycles of systemic chemotherapy

        -  To determine progression free survival at 24 months

        -  To determine overall survival at 1, 3, and 5 years

        -  Evaluate health related quality of life

      Patients who meet study criteria will be randomized into one of two treatment arms: 1)
      cytoreductive surgery (CRS) with carboplatin-based hyperthermic intraperitoneal chemotherapy
      (HIPEC) followed by IV combination chemotherapy with carboplatin and paclitaxel or 2)
      cytoreductive surgery (CRS) alone followed by adjuvant intraperitoneal (IP) and IV
      chemotherapy with combination cisplatin and paclitaxel for newly diagnosed advanced stage
      (stage III/IV) ovarian, fallopian tube or primary peritoneal cancer. Both study arms will
      receive 6 cycles of adjuvant chemotherapy.

      Twenty-four patients will undergo CRS with HIPEC performed by surgical and gynecologic
      oncologic surgeons at Mercy Medical Center, followed by systemic IV chemotherapy with
      carboplatin (AUC=6) and paclitaxel (175mg/m2) for 6 cycles postoperatively.

      Twenty-four patients will undergo CRS only performed by surgical and gynecologic oncologic
      surgeons at Mercy Medical Center, followed by IV/IP chemotherapy with Day 1: IV paclitaxel
      (135 mg/m2), Day 2: IP cisplatin (75 mg/m2), and Day 8: IP paclitaxel (60 mg/m2) for 6 cycles
      postoperatively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative complication rates</measure>
    <time_frame>30 days post-operative</time_frame>
    <description>Compare post-operative complication rates between study arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life</measure>
    <time_frame>Baseline, 4 weeks post-operative, upon completion of systemic chemotherapy, and years 1, 2, 3, 4, &amp; 5</time_frame>
    <description>FACT-O questionnaire to assess quality of life in both study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the rate of progression free survival</measure>
    <time_frame>at 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate overall survival</measure>
    <time_frame>at 1, 3, and 5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Risk factors for morbidity and mortality</measure>
    <time_frame>During &amp; at study completion</time_frame>
    <description>Determine percent of patients wtih Grade I-V adverse events according to NCI criteria, Common Terminology Criteria for AE (CTCAE).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Stage III Ovarian Cancer</condition>
  <condition>Stage IV Ovarian Cancer</condition>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <condition>Ovarian Carcinoma</condition>
  <condition>Fallopian Tube Carcinoma</condition>
  <arm_group>
    <arm_group_label>CRS with adjuvant IV/IP chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo cytoreductive surgery (CRS) alone with IV/IP combination adjuvant chemotherapy. Day 1: IV paclitaxel (135 mg/m2), day 2: IP cisplatin (75 mg/m2), and day 8: IP paclitaxel (60 mg/m2) given every 21 days for a total of 6 cycles. Standard of care treatment. Administration of quality of life questionnaires throughout study duration of follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRS/HIPEC with adjuvant IV chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) administered using carboplatin for 90 minutes. Adjuvant systemic IV combination chemotherapy with carboplatin and paclitaxel (Carboplatin AUC 6, Paclitaxel 175mg/m2) will be given every 21 days for a total of 6 cycles. Administration of quality of life questionnaires throughout study duration of follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cytoreductive Surgery (CRS)</intervention_name>
    <description>Cytoreductive surgery</description>
    <arm_group_label>CRS with adjuvant IV/IP chemotherapy</arm_group_label>
    <arm_group_label>CRS/HIPEC with adjuvant IV chemotherapy</arm_group_label>
    <other_name>CRS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant Chemotherapy</intervention_name>
    <description>Six weeks post-surgery (CRS or CRS/HIPEC) standard combination chemotherapy will be administered every 21 days for 6 cycles</description>
    <arm_group_label>CRS with adjuvant IV/IP chemotherapy</arm_group_label>
    <arm_group_label>CRS/HIPEC with adjuvant IV chemotherapy</arm_group_label>
    <other_name>Post-operative chemotherapy</other_name>
    <other_name>Systemic chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Questionnaires designed to assess quality of life in ovarian cancer patients will be administered to study participants</description>
    <arm_group_label>CRS with adjuvant IV/IP chemotherapy</arm_group_label>
    <arm_group_label>CRS/HIPEC with adjuvant IV chemotherapy</arm_group_label>
    <other_name>FACT-O Questionnaire</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperthermic intraperitoneal chemotherapy</intervention_name>
    <description>Hyperthermic intraperitoneal chemotherapy with carboplatin, AUC=6</description>
    <arm_group_label>CRS/HIPEC with adjuvant IV chemotherapy</arm_group_label>
    <other_name>HIPEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC=6 mg/mL/min IV (in the vein), on day 1. Repeat every 21 days for 6 cycles.</description>
    <arm_group_label>CRS/HIPEC with adjuvant IV chemotherapy</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175 mg/m2 IV (in the vein), day 1. Repeat every 21 days for 6 cycles</description>
    <arm_group_label>CRS/HIPEC with adjuvant IV chemotherapy</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Day 1: paclitaxel 135 mg/m2 IV (in the vein). Repeat every 21 days for 6 cycles Day 8: paclitaxel 60 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles</description>
    <arm_group_label>CRS with adjuvant IV/IP chemotherapy</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Day 2: cisplatin 75 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles</description>
    <arm_group_label>CRS with adjuvant IV/IP chemotherapy</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical presentation of ovarian, fallopian tube or primary peritoneal cancer

          -  Stage III/IV disease

          -  No prior treatment or significant surgery for the management of ovarian, fallopian
             tube, or primary peritoneal carcinoma; History of laparoscopic procedures to obtain
             diagnostic biopsies will be permitted in the study

          -  Histological confirmation

          -  Eastern Cooperative Oncology Group performance status 0-2 or Karnofsky performance
             status ≥ 70%

          -  ≤1 cm residual disease at the completion of the cytoreductive surgery (GOG criteria
             for optimally cytoreduction)

          -  Bone marrow function:

               1. Absolute neutrophil count (ANC) ≥1,000/mm3

               2. Platelets ≥100,000/mm3

               3. Hemoglobin ≥ 8.5 g/dL

          -  Renal function:

             1) Creatinine ≤1.5 times the upper limit of normal or a calculated creatinine
             clearance ≥60ml/min

          -  Hepatic function:

               1. Bilirubin ≤1.5 times upper limit of normal

               2. Alanine aminotransferase (ALT) ≤3 times upper limit of normal

               3. Aspartate aminotransferase (AST) ≤3 times upper limit of normal

          -  Blood coagulation parameters:

               1. Prothrombin time (PT) with International Normalized Ratio of ≤1.5 and a partial
                  prothrombin time (PTT) ≤1.5 times upper limit of normal

               2. For patients on full dose warfarin, in range International Normalized Ratio
                  (usually between 2 and 3) and

               3. Partial prothrombin time (PTT) &lt;1.2 times upper limit of normal

               4. Candidate for administration of postoperative standard platinum-based combination
                  systemic chemotherapy (adequate bone marrow, renal, hepatic function, and blood
                  coagulation parameters)

        Exclusion Criteria:

          -  Any prior treatment modality for the diagnosis of ovarian, fallopian tube, or primary
             peritoneal cancerPrior surgical attempt of cytoreductive surgery

          -  Stage I/II disease

          -  Presence of other invasive malignancies or evidence of other cancer within the past 3
             years

          -  Known active acute hepatitis and confirmed diagnosis of HIV

          -  Active systemic infection that requires use of parenteral antibiotics

          -  History of acute coronary syndromes (ACS), within the last 6 months, according to AHA
             definitions

          -  New York Heart Association (NYHA) Class II or higher congestive heart failure
             according to American Heart Association (AHA) definitions

          -  Canadian Cardiovascular Society (CCS) Class II or higher angina grade according to AHA
             definitions

          -  Uncontrolled hypertension defined as &gt; 140/90 and not cleared for surgery at time of
             consent by cardiologist

          -  History of cerebral artery disease and prior stroke according to AHA definitions in
             the last 6 months

          -  Renal insufficiency with serum creatinine level ≥1.5 times the upper limit of normal
             or calculated creatinine clearance &lt;60 ml/min

          -  Patients with concurrent severe medical problems unrelated to malignancy that will
             preclude compliance with the study or places at an unacceptable risk for participation
             in the study determinate by study investigators

          -  Pregnant women are excluded from this study because carboplatin is category D agent
             with the potential of teratogenic effects. Due to potential risk for adverse events in
             nursing infants secondary to treatment of the mother with carboplatin, breastfeeding
             should be discontinued

          -  Life expectancy of &lt; 12 weeks
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresa Diaz-Montes, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Armando Sardi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Sittig, RN</last_name>
    <phone>410-332-9294</phone>
    <email>msittig@mdmercy.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Teresa Diaz-Montes, M.D., M.P.H</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armando Sardi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2014</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <keyword>Cytoreductive surgery</keyword>
  <keyword>Hyperthermic Intraperitoneal chemotherapy</keyword>
  <keyword>Systemic chemotherapy</keyword>
  <keyword>Primary peritoneal carcinoma</keyword>
  <keyword>Fallopian Tube cancer</keyword>
  <keyword>Intraperitoneal chemotherapy</keyword>
  <keyword>IV/IP chemotherapy</keyword>
  <keyword>IV chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

